24 May 2013
Keywords: paion, candidate, shows, strong, safety, data, german
Article | 12 May 2009
German biopharmaceutical company Paion has reported positive results from the first part of the Phase Ib study with short-acting intravenous
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
23 May 2013
© 2013 thepharmaletter.com